

ASX ANNOUNCEMENT

17 October 2023

Cann receives \$3.484 million R&D tax rebate

17 October 2023 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce it has received a \$3.484 million R&D Tax Incentive Rebate for the 2023 financial year.

The rebate relates to eligible R&D activities conducted by Cann, including its in-house research and those activities conducted through its strategic partnerships with key research partners. The net proceeds to Cann after full repayment of all early advances received from Radium Capital are \$1.915 million.

The Australian Government's R&D Tax Incentive program provides companies with a tax offset for eligible R&D activities. The funds received will be reinvested into the continued development of Cann's end-to-end capabilities of cultivating and manufacturing GMP grade medicinal cannabis products.

Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Jackson Paine Corporate Communications Manager +61 439 492 955 jackson.paine@canngrouplimited.com

For all other information please contact:

Peter KoetsierDeborah AmbrosiniCEOCFOCann Group LimitedCann Group Limited+61 3 9095 7088+61 3 9095 7088contact@canngrouplimited.comdeborah.ambrosini@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouplimited.com | www.satipharm.com